Biotechnology

A new line of ultra-pure proteins with endotoxin levels 10x below the standard could revolutionize advanced therapies and fix a key source of error in science.

Biosolutions leader Novonesis ranks 6th on the prestigious list, a recognition driven by employee feedback and its deep roots in the state's biotech economy.

Relmada Therapeutics stock skyrockets on promising bladder cancer data and a $160M financing deal, setting a high-stakes stage for its investor conference.

AEON Biopharma hires a seasoned CFO to navigate FDA trials and financial hurdles as it aims to launch its BOTOX biosimilar into a lucrative market.

BETA Technologies will launch electric air services across 10 states, deploying its ALIA aircraft for cargo, medical, and critical logistics missions.

The world's top virologists now have a permanent home at the University of South Florida, forging a new global nexus for pandemic preparedness.

A massive investment in Kankakee promises hundreds of jobs and a vital increase in life-saving plasma therapies for patients with rare diseases.

A new, highly selective drug for Duchenne muscular dystrophy shows potential to be safer and more effective, targeting both muscle and heart decline.

A landmark European approval for Elfabrio allows stable Fabry disease patients to switch to monthly infusions, promising greater freedom and lower healthcare strain.

As electroCore preps its 2025 financial report, all eyes are on its product growth, the new Quell device, and its path to profitability in the booming bioelectronic market.

As Capricor prepares its Q4 earnings call, all eyes are on its DMD drug Deramiocel's FDA path, financial health, and next-gen exosome technology.

Medicus Pharma's microneedle patch for basal cell carcinoma clears nearly three-quarters of lesions, offering a potential non-surgical alternative to the scalpel.

With new data on CUE-401, a novel therapy inspired by Nobel-winning science, Cue Biopharma makes a high-stakes play to redefine autoimmune treatment.

Founded by Emma Heming Willis, Make Time Wellness unveils three new products, tapping into a booming market with science-backed solutions for women's brain health.

A year after rebranding from FibroGen, Kyntra Bio's first full-year report will test if its lean strategy can fuel its ambitious oncology pipeline.

With one trial halted and another beginning, the company focuses its cash and hopes on BBI-940, a novel drug targeting a fundamental driver of cancer.

A new AI-designed drug shows promise in selectively burning fat while preserving muscle, with a potential twice-yearly dosing schedule for obesity.

UK's Abselion opens a US base in Cambridge, MA, aiming to disrupt biologics R&D with its rapid Amperia protein quantification system.

IDEAYA Biosciences begins a key trial for its targeted therapy IDE892, aiming to conquer hard-to-treat tumors and pivoting to focus on its proprietary assets.

With its runway extended by insiders, the biotech firm bets on its promising glioblastoma drug and an unconventional strategy of crypto and acquisitions.